MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

Rosa Ayala, David Lavie, Adi Shacham Abulafia et al.|Clinical Lymphoma Myeloma & Leukemia|2023

Cited by 2